Amicus Therapeutics, INC

Amicus Therapeutics, Inc. has been acquired by BioMarin Pharmaceutical Inc. through a merger, with shareholders receiving $14.50 per share in cash.

Amicus Therapeutics announced that the French Ministry of Economics and Finance has granted clearance for its merger with BioMarin Pharmaceutical Inc., satisfying a key condition for the transaction's closure.

Amicus Therapeutics stockholders overwhelmingly approved the company's acquisition by BioMarin Pharmaceutical Inc. at a special meeting held on March 3, 2026.

Amicus Therapeutics disclosed preliminary unaudited 2025 financial results, including $634 million in total net product revenues, amidst its proposed acquisition by BioMarin Pharmaceutical Inc.

BioMarin Pharmaceutical Inc. has entered into a definitive agreement to acquire Amicus Therapeutics for $14.50 per share in an all-cash transaction, totaling approximately $4.8 billion.

Amicus Therapeutics reported strong third-quarter 2025 financial results, achieving GAAP net income of $17 million on total revenues of $169 million, up 17% at constant exchange rates.

Amicus Therapeutics, Inc. reported a significant increase in net product sales and a swing to net income for the third quarter, while substantially reducing its net loss for the first nine months of 2025.

Amicus Therapeutics has entered into an exclusive U.S. licensing agreement for Dimerix's Phase 3 FSGS drug DMX-200, while reporting significant revenue growth for its existing Fabry and Pompe disease therapies.

Amicus Therapeutics' Q1 2025 results show revenue growth driven by Galafold and Pombiliti + Opfolda, alongside a strategic licensing agreement for DMX-200.

Amicus Therapeutics saw a significant increase in revenue during the third quarter of 2024, primarily due to the continued growth of Galafold and the launch of Pombiliti + Opfolda.

Amicus Therapeutics saw a revenue increase in the second quarter of 2024, driven by strong sales of Galafold and the launch of Pombiliti + Opfolda, while also managing operating expenses.

Amicus Therapeutics' first quarter 2024 results show increased revenue driven by growth in Galafold sales and the launch of Pombiliti + Opfolda.

Amicus Therapeutics' 2024 10-K filing reveals significant revenue growth driven by its key products, Galafold and Pombiliti + Opfolda, alongside strategic pipeline advancements and a solid financial position.

Amicus Therapeutics secures global rights to its Fabry disease drug, migalastat, from GlaxoSmithKline, with GSK retaining a financial interest through equity and future payments.

Director Craig A. Wheeler reports the disposal of all equity holdings following the acquisition of Amicus Therapeutics by BioMarin Pharmaceutical Inc.

Director Margaret G. McGlynn reports the disposal of all equity holdings following the completed acquisition of Amicus Therapeutics by BioMarin Pharmaceutical Inc.

Director Burke W. Whitman reports the disposal of all equity holdings following the acquisition of Amicus Therapeutics by BioMarin Pharmaceutical Inc.

Director Glenn Sblendorio reports the disposal of all equity holdings following the acquisition of Amicus Therapeutics by BioMarin Pharmaceutical Inc.

Director Eiry Roberts reports the disposal of all Amicus Therapeutics equity holdings following the company's acquisition by BioMarin Pharmaceutical Inc.

Director Lynn Dorsey Bleil reports the disposal of all Amicus Therapeutics equity holdings following the company's acquisition by BioMarin Pharmaceutical Inc.

Amicus Therapeutics filed additional proxy materials to supplement its definitive proxy statement for the BioMarin merger, addressing multiple stockholder lawsuits and updating financial projections.

Amicus Therapeutics provides preliminary unaudited financial results for 2025, showing robust product revenue growth ahead of its acquisition by BioMarin.

BioMarin Pharmaceutical Inc. will acquire Amicus Therapeutics Inc. for $14.50 per share in an all-cash transaction, expanding its rare disease portfolio.

Amicus Therapeutics has filed a definitive proxy statement with the SEC, signaling upcoming shareholder actions.

Amicus Therapeutics is set to hold its 2025 Annual Meeting of Stockholders virtually on June 5, 2025, to vote on director elections, an equity incentive plan, auditor ratification, and executive compensation.

Amicus Therapeutics has filed a definitive proxy statement with the SEC, signaling upcoming shareholder actions.

Barclays PLC has filed a Schedule 13G reporting a 5.65% beneficial ownership stake in Amicus Therapeutics Inc.

Goldman Sachs Group, Inc. and its subsidiary Goldman Sachs & Co. LLC have reported a beneficial ownership of 5.3% of Amicus Therapeutics, Inc. common stock as of March 31, 2026.

UBS Group AG has filed a Schedule 13G, reporting beneficial ownership of 17,141,817 shares, or approximately 5.5%, of Amicus Therapeutics, Inc. common stock.

Glazer Capital, LLC and Paul J. Glazer have filed an exit notice confirming they no longer beneficially own more than 5% of Amicus Therapeutics, Inc. common stock.

Vanguard Capital Management has reported beneficial ownership of 5.2% of Amicus Therapeutics Inc.'s common stock as of March 31, 2026.

The Vanguard Group has filed an amended Schedule 13G, reporting 0% beneficial ownership in Amicus Therapeutics Inc. following an internal realignment.